# Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

> **NCT02422641** · PHASE2 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 16 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Leptomeningeal Disease

## Interventions

- **DRUG:** High-dose Methotrexate (8 gm/m2; HD-MTX)

## Key facts

- **NCT ID:** NCT02422641
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-05
- **Primary completion:** 2026-05
- **Final completion:** 2027-07
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422641, "Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02422641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*